Pursuing Unexplored Targets to halt and reverse fibrotic activity in the clinic
Mediar is pioneering a novel approach to fibrosis treatment that disables the myofibroblast, the key pathogenic cell in fibrosis that drives scarring, disease progression, and ultimately organ failure
New perspective. Novel targets. Clinical trials.
The myofibroblast is responsible for depositing collagen, extracellular matrix, and maintaining the pro-fibrotic micro-environment in organ systems. By deactivating the myofibroblast, we hope to slow fibrosis and possibly reverse it.
Mediar is running clinical studies in fibrosing diseases to bring new potential options for patients and their caregivers.
Fearlessly Charting a Course Toward Patient Impact
Mediar’s team of industry-leading researchers & clinicians combines deep fibrosis expertise, antibody engineering knowledge, and clinical trial expertise to advance novel programs through approval. We have deep expertise in running late-stage clinical programs in fibrosis and related indications that include IPF, SSc, kidney and other areas.
Passionately Powered by Science for Patient Impact
